44. Wegener granulomatosis
84 clinical trials,   88 drugs   (DrugBank: 22 drugs),   13 drug target genes,   37 drug target pathways
Searched query = "Wegener granulomatosis", "Multiple vasculitis granulomatous disease", "Granulomatosis with polyangiitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03967925 (ClinicalTrials.gov) | February 1, 2019 | 18/1/2019 | Rituximab and Belimumab Combination Therapy in PR3 Vasculitis | A Randomised, Double Blind, Controlled Mechanistic Study of Rituximab and Belimumab Combination Therapy in PR3 ANCA-associated Vasculitis | ANCA Associated Vasculitis;Granulomatosis With Polyangiitis | Drug: Belimumab;Drug: Rituximab;Drug: Prednisolone | Rachel Jones | GlaxoSmithKline;Medical Research Council;Imperial College London;University College, London;Newcastle University;University of Glasgow;University of Cambridge | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | United Kingdom |